

CONTENTS

Statement of—

Beyer, Karl H., Jr., M.D., Ph. D., senior vice president for research, Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., Rahway, N.J.	Page 3311
Calabro, John J., M.D., associate professor of medicine, Department of Medicine, UCLA School of Medicine, Center for the Health Sciences; and chief, Rheumatology Section, Wadsworth Hospital, Veterans' Administration Center, Wilshire and Sawtelle Boulevards, Los Angeles, Calif.	3399
Case, Hon. Clifford P., U.S. Senator, State of New Jersey	3295
Chadduck, Harry, Deputy Director, Division of Medical Advertising, Bureau of Medicine, Food and Drug Administration; accompanied Dr. Robert S. McCleery, Acting Deputy Director, Bureau of Medicine, FDA	3484
Cutler, Lloyd N., special counsel, Washington, D.C.; accompanied Henry W. Gadsden, president, Merck & Co., Inc., Rahway, N.J.	3296, 3429
Gadsden, Henry W., president, Merck & Co., Inc., Rahway, N.J.; accompanied by Lloyd N. Cutler, special counsel, Washington, D.C.	3296, 3429
Goodrich, William W., General Counsel, Food and Drug Administration; accompanied Dr. Robert S. McCleery, Acting Director, Division of Medical Advertising, Bureau of Medicine, FDA	3105, 3484
Lawrason, F. Douglas, M.D., vice president for medical affairs, Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., Rahway, N.J.	3315
Ley, Dr. Herbert L., Director, Bureau of Medicine, Food and Drug Administration; accompanied Dr. Robert S. McCleery, Acting Director, Division of Medical Advertising, Bureau of Medicine, FDA	3105
McCleery, Dr. Robert S., Acting Director, Division of Medical Advertising, Bureau of Medicine, Food and Drug Administration; accompanied by Dr. Herbert L. Ley, Director, Bureau of Medicine, FDA; and William W. Goodrich, General Counsel, FDA	3105
McCleery, Dr. Robert S., Acting Deputy Director, Bureau of Medicine, Food and Drug Administration (second appearance); accompanied by Dr. B. Harvey Minchew, Acting Director, Bureau of Medicine, FDA; Harry Chadduck, Deputy Director, Division of Medical Advertising, Bureau of Medicine, FDA; William W. Goodrich, General Counsel, FDA; and Morton M. Schneider, Assistant Director, Office of Legislative and Governmental Services, FDA	3484
Minchew, Dr. B. Harvey, Acting Director, Bureau of Medicine, Food and Drug Administration; accompanied Dr. Robert S. McCleery, Acting Deputy Director, Bureau of Medicine, FDA	3484
Rothermich, Dr. Norman O., clinical professor of medicine, Ohio State University; senior physician, Columbus Medical Center; medical director, Columbus Medical Center Research Foundation, 1211 Dublin Road, Columbus, Ohio	3262
Schneider, Morton M., Assistant Director, Office of Legislative and Governmental Services, Food and Drug Administration; accompanied Dr. Robert S. McCleery, Acting Deputy Director, Bureau of Medicine, FDA	3484
Scott, Hon. Hugh, U.S. Senator, State of Pennsylvania (written statement)	3451
Smyth, Dr. Charley J., professor of medicine; and director, Division of Rheumatic Disease, University of Colorado Medical Center, 4200 East Ninth Avenue, Denver, Colo.	3425
Tishler, Max, Ph. D., president, Merck Sharp & Dohme Research Laboratories, Division of Merck & Co., Inc., Rahway, N.J.	3303